Información del artículo
La osteoporosis es un problema global cuya importancia va en aumento por el envejecimiento progresivo de la población. La osteoporosis primaria o involutiva es una enfermedad que se caracteriza por una disminución de la resistencia ósea que condiciona un aumento de la susceptibilidad a fracturas por fragilidad. La osteoporosis secundaria incluye aquellas condiciones patológicas, medicaciones y hábitos que reducen la masa ósea y aumentan el riesgo de fractura osteoporótica de forma independiente de la edad y el déficit estrogénico. El presente informe del Grupo de Trabajo de Metabolismo Óseo y Mineral de la SEEN analiza la mejor evidencia científica disponible en relación con la evaluación diagnóstica e intervenciones terapéuticas en pacientes con osteoporosis primaria y secundaria.
Palabras clave:
Osteoporosis primaria
Osteoporosis secundaria
Fractura osteoporótica
Osteoporosis is a global problem that will become increasingly important with progressive population aging. Primary osteoporosis is characterized by reduced bone strength and increased susceptibility to fragility fractures. Secondary osteoporosis encompasses the pathological disorders, medications, and habits that reduce bone mass and increase the risk of osteoporotic fracture independently of aging and estrogen deficiency. This report of the Working Group for Bone and Mineral Metabolism of the Spanish Society of Endocrinology and Nutrition analyzes the best available scientific evidence on diagnostic evaluation and therapeutic interventions in patients with primary and secondary osteoporosis.
Key words:
Primary osteoporosis
Secondary osteoporosis
Osteoporotic fracture
El Texto completo está disponible en PDF
Bibliografía
[1.]
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy.
Osteoporosis prevention, diagnosis, and therapy.
JAMA, 285 (2001), pp. 785-795
[2.]
M. Muñoz-Torres, G. Alonso, P. Mezquita.
Prevención y tratamiento de la osteoporosis.
Endocrinol y Nutr, 50 (2003), pp. 1-7
[3.]
Grupo de trabajo de la SEIOMM.
Osteoporosis posmenopáusica. Guía de práctica clínica.
Rev Cin Esp, 203 (2003), pp. 496-506
[4.]
R. Lindsay, S.L. Silverman, C. Cooper, D.A. Hanley, I. Barton, S.B. Broy, et al.
Risk of new vertebral fracture in the year following a fracture.
JAMA, 285 (2001), pp. 320-323
[5.]
R. Recker, J. Lappe, K.M. Davies, R. Heaney.
Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients.
J Bone Miner Res, 19 (2004), pp. 1628-1633
[6.]
S. Srivastava, G. Toraldo, M.N. Weitzmann, S. Cenci, F.P. Ross, R. Pacifici, et al.
Estrogen decreases osteoclast formation by down regulating RANKL induced JNK activation.
J Biol Chem, 276 (2001), pp. 8836-8840
[7.]
R.P. Heaney.
Vitamin D, nutritional deficiency, and the medical paradigm.
J Clin Endocrinol Metab, 88 (2003), pp. 5107-5108
[8.]
M. De la Higuera López-Frías, D. Fernández García, M. Muñoz-Torres.
Densitometría ósea: usos clínicos y evidencia científica.
Rev Clin Esp, 204 (2004), pp. 480-482
[9.]
WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843. Geneva, 1994.
[10.]
M. Muñoz-Torres, M. De la Higuera López-Frías, D. Fernández García, G. Alonso, R. Reyes García.
Densitometría ósea: indicaciones e interpretación.
Endocrinol Nutr, 52 (2005), pp. 224-227
[11.]
H.K. Genant, M. Jergas.
Assessment of prevalent and incident vertebral fractures in osteoporosis research.
Osteoporos Int, 14 (2003), pp. S43-55
[12.]
P. Mezquita Raya, M. Muñoz Torres, J.D. Luna, V. Luna, F. Lopez-Rodríguez, E. Torres Vela, et al.
Relation between vitamin D insufficiency, bone density, and bone metabolism in healthy postmenopausal women.
J Bone Miner Res, 16 (2001), pp. 1-8
[13.]
M. Muñoz Torres, P. Mezquita, F. López.
Utilidad de los marcadores de remodelado óseo.
Endocrinol Nutr, 47 (2000), pp. 267-276
[14.]
P. Garnero, E. Hausherr, M.C. Chapuy, C. Marcelli, H. Grandjean, C. Muller, et al.
Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study.
J Bone Miner Res, 11 (1996), pp. 1531-1538
[15.]
B.L. Riggs, A.M. Parfitt.
Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling.
J Bone Miner Res, 20 (2005), pp. 177-184
[16.]
R.P. Heany.
Calcium, dairy products and osteoporosis.
J Am Coll Nutr, 19 (2000), pp. 83S-99S
[17.]
M. Muñoz-Torres, M. Sosa Henríquez.
Situación actual de los niveles de vitamina D en la población española.
REEMO, 14 (2005), pp. 19-22
[18.]
M.C. Chapuy, M.E. Arlot, F. Duboeuf, J. Brun, B. Crouzet, S. Arnaud, et al.
Vitamin D3 and calcium to prevent hip fractures in the elderly women.
N Engl J Med, 327 (1992), pp. 1637-1642
[19.]
J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, M.L. Stefanick, et al.
Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial.
JAMA, 288 (2002), pp. 321-333
[20.]
P.D. Delmas, K.E. Ensrud, J.D. Adachi, K.D. Harper, S. Sarkar, C. Gennari, et al.
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.
J Clin Endocrinol Metab, 87 (2002), pp. 3609-3617
[21.]
J.A. Cauley, L. Norton, M.E. Lippman, S. Eckert, K.A. Krueger, D.W. Purdie, et al.
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial.
Breast Cancer Rest Treatment, 65 (2001), pp. 124-134
[22.]
A. Cranney, G. Wells, A. Willan, L. Griffith, N. Zytaruk, V. Robinson, et al.
Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.
Endocr Rev, 23 (2002), pp. 508-516
[23.]
A. Cranney, P. Tugwell, J. Adachi, B. Weaver, N. Zytaruk, A. Papaioannou, et al.
Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis.
Endocr Rev, 23 (2002), pp. 517-523
[24.]
C.H. Chestnut III, S. Silverman, K. Andriano, H. Genant, A. Gimona, S. Harris, et al.
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
Am J Med, 109 (2000), pp. 267-276
[25.]
R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, J.Y. Reginster, et al.
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post-menopausal women with osteoporosis.
N Engl J Med, 344 (2001), pp. 1434-1441
[26.]
P.J. Meunier, C. Roux, E. Seeman, S. Ortolani, J.E. Badurski, T.D. Spector, et al.
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
N Engl J Med, 350 (2004), pp. 459-468
[27.]
M. Stein, E. Shane.
Secondary osteoporosis.
Endocrinol Metab Clin North Am, 32 (2003), pp. 115-134
[28.]
E. Seeman.
Estrogen, androgen, and the pathogenesis of bone fragility in women and men.
Curr Osteoporos Rep, 2 (2004), pp. 90-96
[29.]
J.L. Shaker, B.P. Lukert.
Osteoporosis associated with excess glucocorticoids.
Endocrinol Metab Clin North Am, 34 (2005), pp. 341-356
[30.]
T. Mancini, M. Doga, G. Mazziotti, A. Giustina.
Cushing's syndrome and bone.
Pituitary, (2005),
[31.]
J.P. Bilezikian, S. Silverberg.
Primary Hyperparathyroidism.
Primer on the Metabolic Bone Disease, 5th ed, pp. 230-235
[32.]
J.P. Bilezikian, M.L. Brandi, M. Rubin, S.J. Silverberg.
Primary hyperpara thyroidism: new concepts in clinical, densitometric and biochemical features.
J Intern Med, 257 (2005), pp. 6-17
[33.]
D.S. Ross.
Bone disease with hyperthyroidism and thyroid hormone therapy,
[34.]
LD. Hordon.
Bone disease in diabetes mellitus,
[35.]
R. Pivonello, A. Colao, C. Di Somma, G. Facciolli, M. Klain, A. Faggiano, et al.
Impairment of bone status in patients with central diabetes insipidus.
J Clin Endocrinol Metab, 83 (1998), pp. 2275-2280
[36.]
T. Ueland.
Bone metabolism in relation to alterations in systemic growth hormone.
Growth Horm IGF Res, 14 (2004), pp. 404-417
[37.]
J.Y. Reginster.
The high prevalence of inadequate serum vitamin D levels and implications for bone health.
Curr Med Res Opin, 21 (2005), pp. 579-586
[38.]
B. Dawson-Hughes.
Calcium and vitamin D.
Primer on the Metabolic Bone Disease, 5th ed, pp. 349-351
[39.]
U.A. Liberman.
Disorders in vitamin D action.
Endotext,
[40.]
FORE. Osteoporosis. En: Foundation for Osteoporosis Reasearch and Education, editor. Guidelines for the physician. 4th ed. Oakland: Foundation for Osteoporosis Research and Education; 2002.
[41.]
American Association of Clinical Endocrinologists.
Medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients–2002 update, 8 (2002), pp. 439-456
[42.]
Nelson HD, Haney E, Humphrey L, Miller J, Nedrow A, Nicolaidis C, et al. Summary, Evidence Report/Technology Assessment No. 120. (Prepared by the Oregon Evidence-based Practice Center, under Contract No. 290-02-0024.) AHRQ Publication No. 05-E016-1. Rockville: Agency for Healthcare Research and Quality. March 2005
[43.]
AE. Taylor.
Treatment of spontaneous premature ovarian failure,
[44.]
Guideline Development Group for the Royal College of Physicians. Glucocorticoid-Induced Osteoporosis: Clinical Guidelines for prevention and treatment. London: Royal College of Physicians; 2002. Disponible en: www.rcplondon.ac.uk
[45.]
AACE/AAES Task Force on Primary Hyperparathyroidism.
The American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons. Position statement on the diagnosis and management of primary hyperparathyroidism, 11 (2005), pp. 49-54
[46.]
AACE Thyroid Task Force.
The American Association of Clinical Endocrinologists. Medical Guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism, 8 (2002), pp. 457-469
[47.]
B. Moreno, G. Obiols, C. Páramo, A. Zugasti.
Guía clínica del manejo del prolactinoma y otros estados de hiperprolactinemia.
Endocrinol Nutr, 52 (2005), pp. 9-17
[48.]
R. Pivonello, A. Faggiano, C. Di Somma, M. Klain, M. Filippella, M. Salvatore, et al.
Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus.
J Clin Endocrinol Metab, 84 (1999), pp. 2349-2352
[49.]
A. Gilsanz, A. Picó, E. Torres, C. Varela.
Guía clínica del manejo de la deficiencia de hormona de crecimiento en el adulto.
Endocrinol Nutr, 52 (2005), pp. 22-28
[50.]
AACE Growth Hormone Task Force.
The American Association of Clinical Endocrinologists. Medical Guidelines for Clinical Practice for Growth Hormone Use in Adults and Children-2003 update.
Endocr Pract, 9 (2003), pp. 64-76
[51.]
J.F. Aloia, Z. Petrak, K. Ellis, S.H. Cohn.
Body composition and skeletal metabolism following pituitary irradiation in acromegaly.
Am J Med, 61 (1976), pp. 59-63
[52.]
C.J. Menkes.
Diagnosis and tratment of osteomalacia,
Copyright © 2007. Sociedad Española de Endocrinología y Nutrición
